Intellia Therapeutics (NTLA): New Data Implies Clinical Benefit - Wedbush

August 22, 2016 8:35 AM EDT
Get Alerts NTLA Hot Sheet
Price: $13.80 --0%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 2
Trade NTLA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Wedbush analyst, David Nierengarten, reiterated his Outperform rating on shares of Intellia Therapeutics (NASDAQ: NTLA) after additional data presented on its TTR program which the analyst thinks should correlate to clinical benefit.

On Thursday NTLA presented data showing they were able to achieve up to 60% editing of transthyretin (TTR) gene in the livers of mice following IV administration, which resulted in up to 80% decrease in TTR serum protein levels; this high editing rate was shown to be consistent across individual mice in a study and across liver lobes.

NTLA had previously presented data showing high levels of dose-dependent TTR editing in the liver cells of mice, and he expects to see further improvements in editing efficiency with continued guide RNA optimization. Although early, these results are meaningful and compare favorably with TTR serum reduction achieved by RNAi programs in development, which he notes are associated with only a transient benefit.

No change to the price target of $38.

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $22.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment